| Literature DB >> 18992622 |
Glenn S Kroog1, Robert J Motzer.
Abstract
Renal cell cancer (RCC) is the most common form of cancer of the kidney and accounts for approximately 44,000 cases per year in the United States. Historically, only immunotherapy showed activity in metastatic RCC. The improved survival and quality of life for patients with metastatic RCC over the last several years are direct results of advances made in understanding the development of RCC. Three targeted therapies-sunitinib, sorafenib, and temsirolimus-have been approved for use in the United States recently. Current research is aimed at developing new drugs and combining available drugs to improve upon the responses and survival seen with approved single agents.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18992622 DOI： 10.1016/j.ucl.2008.07.007
Source DB: PubMed Journal: Urol Clin North Am ISSN： 0094-0143 Impact factor: 2.241